Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 7/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | AURKA | O14965 | 3/20 | 0.41 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 2/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.41 |
| ▸ | PAK4 | O96013 | 2/20 | 0.41 |
| ▸ | ABL1 | P00519 | 2/20 | 0.41 |
| ▸ | RET | P07949 | 2/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.41 |
| ▸ | FLT1 | P17948 | 2/20 | 0.41 |
| ▸ | LTK | P29376 | 2/20 | 0.41 |
| ▸ | GRK5 | P34947 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.41 |
| ▸ | CDK8 | P49336 | 2/20 | 0.41 |
| ▸ | CLK2 | P49760 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3229989 | 0.76 | KDM4E (0.50) | DYRK1AALDH1A1AURKAKDM4EMAPT | |
| SCHEMBL30770845 | 0.74 | ALDH1A1 (0.48) | ALDH1A1LRRK2KDM4EMAPTLMNA | |
| SCHEMBL29623085 | 0.74 | KDM4E (0.39) | ALDH1A1AURKAKDM4EMAPTKMT2A | |
| SCHEMBL8044760 | 0.74 | ALDH1A1 (0.39) | ALDH1A1KDM4EMAPTTDP1PIK3CD | |
| SCHEMBL324998 | 0.74 | ALDH1A1 (0.39) | ALDH1A1KDM4EMAPTKMT2AMEN1 | |
| SCHEMBL2190488 | 0.74 | ALDH1A1 (0.48) | ALDH1A1LRRK2KDM4EMAPTLMNA | |
| SCHEMBL8367003 | 0.74 | KDM4E (0.39) | ALDH1A1AURKAKDM4EMAPTKMT2A | |
| SCHEMBL324999 | 0.74 | ALDH1A1 (0.39) | ALDH1A1KDM4EMAPTLMNAKMT2A | |
| SCHEMBL21906548 | 0.74 | ALDH1A1 (0.39) | ALDH1A1KDM4EMAPTMETAP2TDP1 | |
| SCHEMBL27796456 | 0.74 | ALDH1A1 (0.39) | ALDH1A1KDM4EMAPTTDP1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4122936-B1 | NOVEL BORON COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | SFC CO LTD (KR) | 2026-02-25 | — | — | EP | disclosed |
| US-12503477-B2 | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | GENZYME CORPORATION | 2025-12-23 | — | — | US | disclosed |
| US-12473306-B2 | Boron compound and organic light-emitting diode including same | SFC CO., LTD. (KR) | 2025-11-18 | — | — | US | disclosed |
| CN-115210243-B | Novel boron compound and organic light-emitting element comprising same | SFC株式会社 | 2025-06-17 | — | — | CN | disclosed |
| CN-119504726-A | BRD4 inhibitor and preparation method and application thereof | 四川大学华西医院 | 2025-02-25 | — | — | CN | disclosed |
| US-20240217991-A1 | COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS | GENZYME CORPORATION (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240147854-A1 | NOVEL BORON COMPOUND AND ORGANIC LIGHT-EMITTING DIODE INCLUDING SAME | SFC CO., LTD. (KR) | 2024-05-02 | — | — | US | disclosed |
| WO-2024044757-A1 | AMINOPYRIMIDINE AND AMINOTRIAZINE DERIVATIVES AS MYC PROTEIN MODULATORS | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044757-A1 | AMINOPYRIMIDINE AND AMINOTRIAZINE DERIVATIVES AS MYC PROTEIN MODULATORS | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-02-29 | — | — | WO | disclosed |
| EP-4122936-A1 | NOVEL BORON COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | SFC Co., Ltd. (KR) | 2023-01-25 | — | — | EP | disclosed |
| US-6455554-B1 | COMPOUNDS CAPABLE OF AFFECTING NICOTINIC CHOLINERGIC RECEPTORS; TREATOMG CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. | 2002-09-24 | — | — | US | disclosed |
| US-6432954-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. | 2002-08-13 | — | — | US | disclosed |
| EP-1225955-A1 | ARYL OLEFINIC AZACYCLIC, AND ARYL ACETYLENIC AZACYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS INHIBITORS OF NICOTINIC CHOLINERGIC RECEPTORS | Targacept, Inc. (US) | 2002-07-31 | — | — | EP | disclosed |
| US-20020058652-A1 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. | 2002-05-16 | — | — | US | disclosed |
| EP-1185514-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | Targacept, Inc. (US) | 2002-03-13 | — | — | EP | disclosed |
| WO-2002005801-A2 | COMPOSITIONS CONTAINING DIACYLTARTARIC SALTS OF (E)-METANICOTINE | TARGACEPT, INC. (US) | 2002-01-24 | — | — | WO | disclosed |
| WO-2002005798-A2 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL DISORDERS | TARGACEPT, INC. (US) | 2002-01-24 | — | — | WO | disclosed |
| WO-2001032264-A1 | ARYL OLEFINIC AZACYCLIC, AND ARYL ACETYLENIC AZACYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS INHIBITORS OF NICOTINIC CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2001-05-10 | — | — | WO | disclosed |
| WO-2000075110-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TARGACEPT, INC. (US) | 2000-12-14 | — | — | WO | disclosed |
| US-4898872-A | Imidazo[4,5-b]pyridyl quinolone cardiac stimulants | PFIZER INC. (US) | 1990-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058652-A1 | Pharmaceutical compositions and methods for use | CYP3A7, AADAC, CYP2B6 | SMN1; SMN2 4604/4885DYRK1A 4075/4885DYRK1B 4417/4885 |
| US-12473306-B2 | Boron compound and organic light-emitting diode including same | CLTB, CD79B, CYBA | SMN1; SMN2 3644/4885DYRK1A 2929/4885DYRK1B 2424/4885 |
| US-20240217991-A1 | COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS | CSF1R, CSF3R, IL1RN | SMN1; SMN2 3838/4885DYRK1A 4321/4885DYRK1B 4079/4885 |
| US-12503477-B2 | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | CSF1R, CSF3R, IL1RN | SMN1; SMN2 3765/4885DYRK1A 3699/4885DYRK1B 3347/4885 |
| US-20240147854-A1 | NOVEL BORON COMPOUND AND ORGANIC LIGHT-EMITTING DIODE INCLUDING SAME | CLTB, CD79B, CYBA | SMN1; SMN2 3888/4885DYRK1A 2613/4885DYRK1B 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.